An Adjudication Algorithm for Respiratory-related Hospitalisation in Idiopathic Pulmonary Fibrosis

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2024 Jan 30

PMID 38288082

Authors

Paul Ford

Michael Kreuter

Kevin K Brown

Wim A Wuyts

Marlies Wijsenbeek

Dominique Israel-Biet

Richard Hubbard

Steven D Nathan

Hilario Nunes

Bjorn Penninckx

Niyati Prasad

Ineke Seghers

Paolo Spagnolo

Nadia Verbruggen

Nik Hirani

Juergen Behr

Robert J Kaner

Toby M Maher

Affiliations

Soon will be listed here.

Abstract

Background: There is no standard definition of respiratory-related hospitalisation, a common end-point in idiopathic pulmonary fibrosis (IPF) clinical trials. As diverse aetiologies and complicating comorbidities can present similarly, external adjudication is sometimes employed to achieve standardisation of these events.

Methods: An algorithm for respiratory-related hospitalisation was developed through a literature review of IPF clinical trials with respiratory-related hospitalisation as an end-point. Experts reviewed the algorithm until a consensus was reached. The algorithm was validated using data from the phase 3 ISABELA trials (clinicaltrials.gov identifiers NCT03711162 and NCT03733444), by assessing concordance between nonadjudicated, investigator-defined, respiratory-related hospitalisations and those defined by the adjudication committee using the algorithm.

Results: The algorithm classifies respiratory-related hospitalisation according to cause: extraparenchymal (worsening respiratory symptoms due to left heart failure, volume overload, pulmonary embolism, pneumothorax or trauma); other (respiratory tract infection, right heart failure or exacerbation of COPD); "definite" acute exacerbation of IPF (AEIPF) (worsening respiratory symptoms within 1 month, with radiological or histological evidence of diffuse alveolar damage); or "suspected" AEIPF (as for "definite" AEIPF, but with no radiological or histological evidence of diffuse alveolar damage). Exacerbations ("definite" or "suspected") with identified triggers (infective, post-procedural or traumatic, drug toxicity- or aspiration-related) are classed as "known AEIPF"; "idiopathic AEIPF" refers to exacerbations with no identified trigger. In the ISABELA programme, there was 94% concordance between investigator- and adjudication committee-determined causes of respiratory-related hospitalisation.

Conclusion: The algorithm could help to ensure consistency in the reporting of respiratory-related hospitalisation in IPF trials, optimising its utility as an end-point.

References

Maher T, van der Aar E, Van de Steen O, Allamassey L, Desrivot J, Dupont S . Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018; 6(8):627-635. DOI: 10.1016/S2213-2600(18)30181-4. View

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L . Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019; 20(1):71. PMC: 6458653. DOI: 10.1186/s12931-019-1037-7. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171(9):1040-7. DOI: 10.1164/rccm.200404-571OC. View

Brown A, Fischer C, Shlobin O, Buhr R, Ahmad S, Weir N . Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2014; 147(1):173-179. DOI: 10.1378/chest.13-2424. View

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

Maher T, Bendstrup E, Dron L, Langley J, Smith G, Khalid J . Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021; 22(1):197. PMC: 8261998. DOI: 10.1186/s12931-021-01791-z. View

Dempsey T, Sangaralingham L, Yao X, Sanghavi D, Shah N, Limper A . Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019; 200(2):168-174. DOI: 10.1164/rccm.201902-0456OC. View

Maher T, Whyte M, Hoyles R, Parfrey H, Ochiai Y, Mathieson N . Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Adv Ther. 2015; 32(10):929-43. PMC: 4635174. DOI: 10.1007/s12325-015-0249-6. View

10.

Raghu G, van den Blink B, Hamblin M, Brown A, Golden J, Ho L . Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018; 319(22):2299-2307. PMC: 6134440. DOI: 10.1001/jama.2018.6129. View

11.

Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

12.

Parker J, Glaspole I, Lancaster L, Haddad T, She D, Roseti S . A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017; 197(1):94-103. DOI: 10.1164/rccm.201704-0784OC. View

13.

Kreuter M, Polke M, Walsh S, Krisam J, Collard H, Chaudhuri N . Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J. 2020; 55(4). DOI: 10.1183/13993003.01760-2019. View

14.

Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P . Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines. 2021; 9(9). PMC: 8465039. DOI: 10.3390/biomedicines9091237. View

15.

Crestani B, Huggins J, Kaye M, Costabel U, Glaspole I, Ogura T . Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018; 7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4. View

16.

Moua T, Westerly B, Dulohery M, Daniels C, Ryu J, Lim K . Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis. Chest. 2016; 149(5):1205-14. DOI: 10.1016/j.chest.2015.12.026. View

17.

Durheim M, Collard H, Roberts R, Brown K, Flaherty K, King Jr T . Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015; 3(5):388-96. PMC: 4760351. DOI: 10.1016/S2213-2600(15)00093-4. View

18.

Rosas I, Goldberg H, Collard H, El-Chemaly S, Flaherty K, Hunninghake G . A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2017; 153(1):94-104. PMC: 6026220. DOI: 10.1016/j.chest.2017.09.052. View

19.

Raghu G, Amatto V, Behr J, Stowasser S . Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015; 46(4):1113-30. DOI: 10.1183/13993003.02316-2014. View

20.

Collard H, Moore B, Flaherty K, Brown K, Kaner R, King Jr T . Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176(7):636-43. PMC: 2094133. DOI: 10.1164/rccm.200703-463PP. View